Intellia Therapeutics (NTLA) Change in Accured Expenses (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Change in Accured Expenses for 12 consecutive years, with -$11.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 17.12% year-over-year to -$11.9 million; the TTM figure through Mar 2026 stood at -$2.8 million (down 17.04% YoY), while the FY2025 annual figure was -$5.3 million, up 49.23% from the prior year.
• Change in Accured Expenses retreated to -$11.9 million in Q1 2026 per NTLA's latest filing, from $9.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $13.6 million in Q3 2022 and bottomed at -$22.4 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$332529.4 across 5 years, with a median of $3.0 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 220.06% — and 2023, when it sank 367.9%.
• Intellia Therapeutics' Change in Accured Expenses stood at $3.1 million in 2022, then soared by 194.01% to $9.0 million in 2023, then sank by 56.23% to $4.0 million in 2024, then soared by 128.36% to $9.0 million in 2025, then tumbled by 232.35% to -$11.9 million in 2026.
• Business Quant data shows NTLA's Change in Accured Expenses at -$11.9 million in Q1 2026, $9.0 million in Q4 2025, and -$715000.0 in Q3 2025.